港股異動 | 奧思集團(1161.HK)漲超21% 中期純利同比增長34.1%
格隆匯5月31日丨奧思集團(1161.HK)高開高走,現報1.36港元,大漲21.43%,暫成交1527萬港元,最新市值9億港元。奧思集團上週五(28日)晚間公佈截至3月31日止6個月業績稱,期內收益3.15億港元,同比下跌14%;期內溢利為5880萬港元,上升34.1%;每股盈利8.7港仙,中期股息每股5.5港仙。集團對旗下所有品牌的價值均充滿信心,並將繼續尋求在切實可行的地方開設新店以支持其發展,以把握新的增長機會。此外,集團計劃在將軍澳中心開設一間新的水磨坊美容中心,預計於2021年6月開業,與同一個購物中心的現有Glycel門市相輔相成。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.